Clinical Trials Browser

Phase 2 × Insulinoma × Gastrointestinal × Clear all

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 15 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT01056601 2017-12-28

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Phase 2 Terminated

7 enrolled 8 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary